Handelsavisen
prelaunch
Companies Healthcare 6483.TWO
64
6483.TWO TPEx Biotechnology & Medical Research

6483.Two

$13,05
Open in Charts → Attach watcher ⌖
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
869,0M TWD
P/E
EV / Rev
Div yield
0,00 %
Op margin
-27 453,0 %
ROE
-64,3 %
Net margin
-26 643,0 %
Debt / equity
0,07
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

6483.TWO is a biotechnology company engaged in pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.

Business. 6483.TWO is a biotechnology company engaged in pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-64,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6483.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6483.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    6483.TWO is a biotechnology company engaged in pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a high proportion of equity, with total equity of TWD 157,838,000 and total liabilities of TWD 26,097,000, resulting in a debt-to-equity ratio of 0.07. The liquidity position is strong, as evidenced by a current ratio of 9.74 and cash and equivalents of TWD 133,851,000. The price-to-book ratio of 5.46 suggests that the market is valuing the company's equity at a premium relative to its book value.

    Profitability metrics indicate significant challenges, with a net loss of TWD 101,510,000 and an operating loss of TWD 104,596,000. The return on equity of -64.31% and return on assets of -55.19% highlight the company's inability to generate returns from its equity and asset base. These figures are notably worse than the industry median, indicating underperformance in profitability and returns.

    The company's revenue is not segmented by geographic region or product line in the provided data, making it difficult to assess geographic exposure or revenue concentration. However, the absence of disclosed segments suggests that the company may have a concentrated revenue base, which could pose a concentration risk if not diversified.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The operating cash flow of -TWD 96,009,000 and free cash flow of -TWD 94,371,000 indicate a lack of positive cash generation, which could hinder future growth initiatives. The capital expenditure of -TWD 949,000 suggests minimal investment in long-term assets, which may limit the company's ability to scale operations.

    Risk factors include a low liquidity risk and a low dilution risk, as no immediate filing-based liquidity or dilution flags were detected. The company's low debt levels and strong cash position reduce the likelihood of liquidity stress. However, the significant net loss and negative returns suggest that the company may need to raise additional capital in the future, which could lead to dilution for existing shareholders.

    Recent events, as reflected in the financial data, show a continued pattern of losses and negative cash flows. The company's financial statements do not indicate any recent significant events or strategic initiatives that could alter its current trajectory. The absence of positive cash flows and the high price-to-revenue ratio of 1941.39 suggest that the market may be valuing the company based on future expectations rather than current performance.

    Key takeaways
    • The company has a strong liquidity position with a high current ratio and significant cash reserves.
    • Profitability is severely underperforming, with negative returns on equity and assets.
    • The company's capital structure is equity-heavy, with minimal debt.
    • The company is not generating positive cash flows, which could limit its ability to fund growth.
    • There are no immediate liquidity or dilution risks, but the financial performance raises concerns about long-term sustainability.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $13,05
    Market cap
    $862.3M
    Enterprise value
    $739.7M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    5.5x
    P / Tangible book
    5.5x
    Tangible book
    $157.8M
    Net cash
    $122.7M
    Current ratio
    9.7
    Debt / equity
    0.1
    ROA
    -55.2%
    ROE
    -64.3%
    Cash conversion
    95.0%
    CapEx / revenue
    -2.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-27 453,0 %Bottom quartile
    Net Margin-26 643,0 %Bottom quartile
    ROE-64,3 %Bottom quartile
    Capex / Rev-249,1 %Bottom quartile
    D/E0,07Below median
    Cash Conv0,95Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 6483.TWO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6483.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage